{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination can broaden tumor antigen presentation and enhance visibility to T cells via MHC-I pathways.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |",
          "line_ref": "L28"
        },
        {
          "quote": "| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |",
          "line_ref": "L29"
        }
      ],
      "caveat": "The report presents pooled preclinical findings and does not specify whether these gains are uniform across every model tested."
    },
    {
      "claim_id": "C02",
      "claim": "The intervention induces an interferon-rich state that is linked to mechanistic sensitization to checkpoint blockade.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |",
          "line_ref": "L31"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "A causal mediation chain is proposed from expression changes to outcome, but human data are retrospective and observational."
    },
    {
      "claim_id": "C03",
      "claim": "Type I interferon signaling appears necessary for the sensitization effect because anti-IFNAR1 blockade removes benefit.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "The report indicates directional loss of effect with IFNAR1 blockade, but does not provide quantitative magnitude of that loss."
    },
    {
      "claim_id": "C04",
      "claim": "In the human retrospective cohort, prior SARS-CoV-2 mRNA vaccination was associated with improved ICI outcomes compared with no prior vaccination.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        },
        {
          "quote": "Human retrospective metastatic cohort: 130 patients total.",
          "line_ref": "L21"
        }
      ],
      "caveat": "The authors caution this analysis is retrospective and non-randomized, so residual confounding and selection bias may influence observed associations."
    },
    {
      "claim_id": "C05",
      "claim": "Combined mRNA vaccine and anti-PD-L1 intervention improved tumor control in mice and aligns with better outcomes in the human cohort.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.",
          "line_ref": "L14"
        }
      ],
      "caveat": "The human translational signal is retrospective, while the mouse arm is preclinical, so the combined causal interpretation is suggestive not definitive."
    }
  ]
}